Ablynx raises $200m in Nasdaq listing after drug success

By Sam Kerr
24 Oct 2017

Ablynx, the Belgian biopharmaceutical firm, has raised $200m through a second listing in the US, following positive momentum in the development of a new drug designed to combat a life-threatening blood clotting disorder.

Ablynx issued 11.4m of new American Depositary Shares, listed on Nasdaq and offered to investors in the US and Canada. The ADSs represent one ordinary share each. 

The bookrunners were Bank of America Merrill LynchJP Morgan and Jefferies. Robert Baird, Bryan Garnier and Ladenburg Thalmann were co-managers.

The company had ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.